SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACMI - Accumed Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Frank Buck who wrote (1015)1/8/1998 3:12:00 PM
From: Dana Winrow  Read Replies (1) of 1894
 
Frank has asked about the impact of an HPV vaccine on the cytopathology industry and AccuMed in particular.

Cervical cancer, like most cancers, develops over many years. As such, it would take many years before a significant impact on cervical cancer prevalence by an HPV vaccine could be detected. AccuMed is already developing other technologies related to specific markers and probes for disease detection. These will include other organ systems for cancer detection as well as other disease processes (e.g. infectious disease).

I do not know what the target date is for the development of an HPV vaccine.

Dana Winrow
Director, Investor Relations
AccuMed International, Inc.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News